Episode 319: ASCO 2024: A Preview of GU Data

FromThe Uromigos

Start listening View podcast show

Episode 319: ASCO 2024: A Preview of GU Data

FromThe Uromigos

ratings:

Length:

34 minutes

Released:

May 19, 2024

Format:

Podcast episode

Description

What to see at the ASCO 2024 Annual Meeting, with Silke Gillessen.

Released:

May 19, 2024

Format:

Podcast episode

Titles in the series (100)

Broadcasting the latest developments in GU cancer

Skip carousel

Episode 3: Pembrolizumab in Non-Muscle Invasive Bladder Cancer by The Uromigos
33 min listen
Episode 2: The Current role of IO in Front-line Advanced Urothelial Cancer by The Uromigos
30 min listen
Episode 7: The First Uromigos Prostate Cancer Podcast by The Uromigos
26 min listen
Episode 12: COVID-19 in Cancer Patients - The Seattle Experience by The Uromigos
26 min listen
Episode 14: A Discussion about Tocilizumab and COVID-19 with Dr. Nick Mark from Seattle by The Uromigos
15 min listen
Episode 19: Professor Monty Pal discusses the treatment of non-clear cell renal cancer by The Uromigos
18 min listen
Episode 4: Treatment Choices in Front Line Advanced Renal Cancer by The Uromigos
27 min listen
Episode 9: COVID-19 and Cancer: An International Perspective by The Uromigos
22 min listen
Episode 1: Introduction to Uromigos Podcasts by The Uromigos
3 min listen
Episode 21: Treating cancer patients over the next year in the era of COVID-19 by The Uromigos
13 min listen
Episode 17: Dr. Toni Choueiri discusses cancer trials and meetings during COVID-19 by The Uromigos
22 min listen
Episode 20: Treating GU Cancer Patients with acute COVID-19 Infection by The Uromigos
13 min listen
Episode 34: Savolitinib in Renal Papillary Cancer - A Major Breakthrough? by The Uromigos
21 min listen
Episode 8: COVID-19 and Cancer Patients by The Uromigos
22 min listen
Episode 10: COVID-19 and Renal Cancer: A Patient's Perspective by The Uromigos
27 min listen
Episode 6: Urothelial Cancer Highlights from ASCO GU 2020 by The Uromigos
20 min listen
Episode 30: Update on Axitinib plus Pembrolizumab in Renal Cancer (KEYNOTE 426) by The Uromigos
20 min listen
Episode 11: COVID-19 and Immune Checkpoint Inhibitors for the Treatment of Cancer by The Uromigos
18 min listen
Episode 26: Joaquim Bellmunt and Muscle Invasive Bladder Cancer prior to ASCO 2020 by The Uromigos
22 min listen
Episode 5: Renal Highlights from ASCO GU 2020 by The Uromigos
10 min listen
Episode 18: COVID-19: Addressing Renal Cancer Patients’ Concerns by The Uromigos
25 min listen
Episode 16: Treatments and Trials for COVID-19 by The Uromigos
26 min listen
Episode 67: The Third Uromigos Debate - PD1/VEGF vs PD1/CTLA4 for front line renal cancer by The Uromigos
29 min listen
Episode 45: The Uromigos World Tour arrives in Japan by The Uromigos
20 min listen
Episode 13: COVID-19 and Hydroxychloroquinine Existing Data and Ongoing Trials by The Uromigos
19 min listen
Episode 23: Atezolizumab and Enzalutamide versus Enzalutamide Prostate Cancer by The Uromigos
23 min listen
Episode 36: Dr. Tian Zhang discusses three ASCO bladder cancer abstracts with immune therapy/targeted therapy combinations by The Uromigos
21 min listen
Episode 22: COVID-19 and Cardiovascular Disease by The Uromigos
18 min listen
Episode 24: A Study of COVID-19 in Lung Cancer Shows High Mortality by The Uromigos
20 min listen
Episode 15: COVID-19 and Bladder Cancer Surgery by The Uromigos
15 min listen

More Episodes from The Uromigos

Skip carousel

Discover this podcast and so much more

Episode 319: ASCO 2024: A Preview of GU Data

Episode 319: ASCO 2024: A Preview of GU Data

Description

Titles in the series (100)

More Episodes from The Uromigos